期刊文献+
共找到120篇文章
< 1 2 6 >
每页显示 20 50 100
^(125)I粒子植入在难治性甲状腺癌治疗中的应用价值
1
作者 龚成鹏 张雅婧 +1 位作者 胡胜清 高再荣 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2024年第2期269-274,共6页
作为近距离放射治疗的一种,^(125)I粒子植入已广泛应用于各种不可切除或局部复发的恶性肿瘤治疗中,均展现出良好的治疗效果与前景。由于具有疗效确切、安全微创的特点,^(125)I粒子植入为不能再次手术、^(131)I治疗不可控及不适合靶向治... 作为近距离放射治疗的一种,^(125)I粒子植入已广泛应用于各种不可切除或局部复发的恶性肿瘤治疗中,均展现出良好的治疗效果与前景。由于具有疗效确切、安全微创的特点,^(125)I粒子植入为不能再次手术、^(131)I治疗不可控及不适合靶向治疗的持续或复发甲状腺癌提供了一种可选择的手段。该文将简要介绍^(125)I粒子植入在难治性甲状腺癌局部复发灶及其转移灶治疗和病灶术前定位中的应用。 展开更多
关键词 ^^(125)I粒子植入 难治性甲状腺癌 近距离放射治疗
下载PDF
A pilot study on combination of cryosurgery and ^(125)iodine seed implantation for treatment of locally advanced pancreatic cancer 被引量:38
2
作者 Ke-Cheng Xu Li-Zhi Niu +4 位作者 Yi-Ze Hu Wei-Bing He Yi-Song He Ying-Fei Li Jian-Sheng Zuo 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第10期1603-1611,共9页
AIM: To study the therapeutic value of combination o cryosurgery and 125iodine seed implantation for locally advanced pancreatic cancer. METHODS: Forty-nine patients with locally advanced pancreatic cancer (males 36, ... AIM: To study the therapeutic value of combination o cryosurgery and 125iodine seed implantation for locally advanced pancreatic cancer. METHODS: Forty-nine patients with locally advanced pancreatic cancer (males 36, females 13), with a median age of 59 years, were enrolled in the study. Twelve patients had liver metastases. In all cases the tumors were considered unresectable after a comprehensive evaluation. Patients were treated with cryosurgery, which was performed intraoperatively or percutaneously unde guidance of ultrasound and/or computed tomography (CT), and 125iodine seed implantation, which was performed during cryosurgery or post-cryosurgery under guidance of ultrasound and/or CT. A few patients received regional celiac artery chemotherapy. RESULTS: Thirteen patients received intraoperative cryosurgery and 36 received percutaneous cryosurgery Some patients underwent repeat cryosurgery. 125Iodine seed implantation was performed during freezing procedure in 35 patients and 3-9 d after cryosurgery in 14 cases. Twenty patients, 10 of whom had hepaticmetastases received regional chemotherapy. At 3 mo after therapy, CT was repeated to estimate tumor response to therapy. Most patients showed varying degrees of tumor necrosis. Complete response (CR) of tumor was seen in 20.4% patients, partial response (PR), in 38.8%, stable disease (SD), in 30.6%, and progressive disease (PD), in 10.2%. Adverse effects associated with cryosurgery included upper abdomen pain and increased serum amylase. Acute pancreatitis was seen in 6 patients one of whom developed severe pancreatitis. All adverse effects were controlled by medical management with no poor outcome. There was no therapy-related mortality. During a median follow-up of 18 mo (range of 5-40), the median survival was 16.2 mo, with 26 patients (53.1%) surviving for 12 mo or more. Overall, the 6-, 12-, 24- and 36-mo survival rates were 94.9%, 63.1%, 22.8% and 9.5%, respectively. Eight patients had survival of 24 mo or more. The patient with the longest survival (40 mo) is still living without evidence of tumor recurrence. CONCLUSION: Cryosurgery, which is far less invasive than conventional pancreatic resection, and is associated with a low rate of adverse effects, should be the treatment of choice for patients with locally advanced pancreatic cancer. 125Iodine seed implantation can destroy the residual surviving cancer cells after cryosurgery. Hence, a combination of both modalities has a complementary effect. 展开更多
关键词 Pancreatic cancer CRYOSURGERY CRYOABLATION ^^125iodine seed implantation
下载PDF
DTI and pathological changes in a rabbit model of radiation injury to the spinal cord after ^(125)I radioactive seed implantation 被引量:4
3
作者 Xia Cao Le Fang +2 位作者 Chuan-yu Cui Shi Gao Tian-wei Wang 《Neural Regeneration Research》 SCIE CAS CSCD 2018年第3期528-535,共8页
Excessive radiation exposure may lead to edema of the spinal cord and deterioration of the nervous system. Magnetic resonance imaging can be used to judge and assess the extent of edema and to evaluate pathological ch... Excessive radiation exposure may lead to edema of the spinal cord and deterioration of the nervous system. Magnetic resonance imaging can be used to judge and assess the extent of edema and to evaluate pathological changes and thus may be used for the evaluation of spinal cord injuries caused by radiation therapy. Radioactive ^125I seeds to irradiate 90% of the spinal cord tissue at doses of 40–100 Gy (D90) were implanted in rabbits at T10 to induce radiation injury, and we evaluated their safety for use in the spinal cord. Diffusion tensor imaging showed that with increased D90, the apparent diffusion coefficient and fractional anisotropy values were increased. Moreover, pathological damage of neurons and microvessels in the gray matter and white matter was aggravated. At 2 months after implantation, obvious pathological injury was visible in the spinal cords of each group. Magnetic resonance diffusion tensor imaging revealed the radiation injury to the spinal cord, and we quantified the degree of spinal cord injury through apparent diffusion coefficient and fractional anisotropy. 展开更多
关键词 nerve regeneration brachytherapy ^^125i radioactive seeds magnetic resonance imaging radiation injury of the spinal cord diffusion tensor imaging apparent diffusion coefficient fractional anisotropy neural regeneration
下载PDF
Percutaneous biliary stent combined with brachytherapy using 125I seeds for treatment of unresectable malignant obstructive jaundice:A meta-analysis 被引量:4
4
作者 Wei-Yue Chen Chun-Li Kong +11 位作者 Miao-Miao Meng Wei-Qian Chen Li-Yun Zheng Jian-Ting Mao Shi-Ji Fang Li Chen Gao-Feng Shu Yang Yang Qiao-You Weng Min-Jiang Chen Min Xu Jian-Song Ji 《World Journal of Clinical Cases》 SCIE 2021年第35期10979-10993,共15页
BACKGROUND Malignant obstructive jaundice(MOJ)is a common pathologic manifestation of malignant biliary obstruction.Recently,several clinical trials have explored the clinical effectiveness of intraluminal^(125)I seed... BACKGROUND Malignant obstructive jaundice(MOJ)is a common pathologic manifestation of malignant biliary obstruction.Recently,several clinical trials have explored the clinical effectiveness of intraluminal^(125)I seed-based brachytherapy for MOJ patients,and various outcomes have been reported.AIM To assess the efficacy and safety of percutaneous biliary stents with^(125)I seeds compared to conventional metal stents in patients with unresectable MOJ.METHODS A systematic search of English-language databases(PubMed,Embase,Cochrane Library,and Web of Science)was performed to identify studies published prior to June 2020 that compared stents with or without^(125)I seeds in the treatment of unresectable MOJ.The outcomes analyzed included primary outcomes(stent patency and overall survival)and secondary outcomes(complications and liver function parameters).RESULTS Six randomized controlled trials and four retrospective studies involving 875 patients were eligible for the analysis.Of the 875 included patients,404 were treated with^(125)I seed stents,while 471 were treated with conventional stents.Unadjusted pooled analysis demonstrated that compared to conventional stents,^(125)I seed stents extended the stent patency time[hazard ratio(HR)=0.36,95%confidence interval(CI)=0.28-0.45,P<0.0001]and overall survival period(HR=0.52,95%CI=0.42–0.64,P<0.00001).Subgroup analyses based on the type of^(125)I seed stent and type of study design showed consistent results.However,there were no significant differences in the occurrence of total complications[odds ratio(OR)=1.12,95%CI=0.75-1.67,P=0.57],hemobilia(OR=1.02,95%CI=0.45-2.3,P=0.96),pancreatitis(OR=1.79,95%CI=0.42-7.53,P=0.43),cholangitis(OR=1.13,95%CI=0.60-2.13,P=0.71),or pain(OR=0.67,95%CI=0.22-2,P=0.47).In addition,there were no reductions in the levels of serum indices,including total bilirubin[mean difference(MD)=10.96,95%CI=-3.56-25.49,P=0.14],direct bilirubin(MD=7.37,95%CI=-9.76-24.5,P=0.4),alanine aminotransferase(MD=7.52,95%CI=-0.71-15.74,P=0.07),and aspartate aminotransferase(MD=-4.77,95%CI=-19.98-10.44,P=0.54),after treatment.Publication bias was detected regarding the outcome overall survival;however,the conclusions were not changed after the adjustment.CONCLUSION Placement of stents combined with brachytherapy using^(125)I seeds contributes to a longer stent patency and higher overall survival than placement of conventional stents without extra complications or severe liver damage.Thus,it can be considered an effective and safe treatment for unresectable MOJ. 展开更多
关键词 Malignant obstructive jaundice brachytherapy 125i seed PATENCY Survival META-ANALYSIS
下载PDF
Similar therapeutic effects of ^(125I) seed radiotherapy andγ-ray radiotherapy on lacrimal gland adenoid cystic carcinoma 被引量:5
5
作者 Rui Liu Ji-Tong Shi +4 位作者 Xin Ge Ben-Tao Yang Hong Zhang Jing-Xue Zhang Jian-Min Ma 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2021年第4期547-553,共7页
AIM:To evaluate the survival outcomes of patients with lacrimal gland adenoid cystic carcinoma who underwent eye-sparing surgery combined with ^(125I)seed implantation radiotherapy or local externalγ-ray radiotherapy... AIM:To evaluate the survival outcomes of patients with lacrimal gland adenoid cystic carcinoma who underwent eye-sparing surgery combined with ^(125I)seed implantation radiotherapy or local externalγ-ray radiotherapy.METHODS:In this retrospective comparative case series,the clinical records of 27 primary and 8 recurrent patients were reviewed.Univariate and multivariate analyses were used to identify risk factors associated with distant metastasis(DM),and the overall survival(OS)after the initial surgery was analyzed.RESULTS:The median follow-up after radiotherapy was 36 mo(range 6-120 mo).At the last follow-up after radiotherapy,26(74.3%)patients had no evidence of disease,7(20%)patients had DM,2(5.9%)patients died of DM,and 1 patient with DM was lost to follow-up.Univariate analyses showed that duration of symptoms,bone destruction,T stage classification,and wide excision surgery were risk factors influencing DM(P<0.05).The 5-year and 10-year OS rates after the initial surgery were 95.8%and 79.9%,respectively.The 5-year DM-free survival and disease-free survival rates after radiotherapy were 66.4%and 52.7%,respectively.CONCLUSION:^(125I)seed radiotherapy and local externalγ-ray radiotherapy may have similar therapeutic effects in preventing DM.Patients with T1/T2 stage disease have a better prognosis than those with T3/T4 stage disease. 展开更多
关键词 adenoid cystic carcinoma lacrimal gland ^^(125i)seed radiotherapy γ-ray radiotherapy surgical excision
下载PDF
Dosimetry for ^(125) I radioactive seed implantation therapy for hepatocellular carcinoma 被引量:3
6
作者 Jin Lue Xiufeng Cao 《Journal of Nanjing Medical University》 2008年第5期269-272,共4页
Hepatocellular carcinoma (HCC) is an aggressive malignancy. Early lesions respond well to hepatic resection or liver transplantation. However, only a few of HCC patients are suitable for surgical intervention. Exter... Hepatocellular carcinoma (HCC) is an aggressive malignancy. Early lesions respond well to hepatic resection or liver transplantation. However, only a few of HCC patients are suitable for surgical intervention. External beam radiation and chemotherapy is poorly efficacious. In the last 20 years, HCCs belonging to the radiosensitive tumor group has been confirmed. Along with the development of new radiotherapy technology and facilities, the research about brachytherapy(especially ^125I seed implantation therapy) has provoked more interests in the world. Radioactive seed implantation therapy is a form of interstitial brachytherapy, with the property of local "conformal radiotherapy" and the advantages of minimal invasion, convenience, high performance, and minimal adverse effects. It is a promising therapy for HCC, however the dosimetry hasn' t yet been identified and lacks verification in prospective research. This report aims to further explore the best prescription dose and radioactivity for ^125I interstitial implantation brachytherapy for HCC. 展开更多
关键词 carcinoma hepatocellular/radiotherapy brachytherapy radioactive seeds ^^125i
下载PDF
A prospective study:intraoperative ^(125)I radioactive seed implant therapy in advanced esophageal squamous cell carcinoma 被引量:1
7
作者 Jin Lü Xiufeng Cao Bin Zhu Lü Ji 《Journal of Nanjing Medical University》 2009年第5期335-339,共5页
Objective: To investigated the role of intraoperative iodine-125 (125I) brachytherapy as a treatment option for advanced thoracic esophageal squamous cell carcinoma (ESCC). Methods: Using preoperative computed t... Objective: To investigated the role of intraoperative iodine-125 (125I) brachytherapy as a treatment option for advanced thoracic esophageal squamous cell carcinoma (ESCC). Methods: Using preoperative computed tomography (CT)-based staging criteria, between 2000 and 2008, 298 patients with ESCC (stage Ⅱ-Ⅲ) were enrolled in this prospective study. With informed consent, patients were randomized into two groups: intraoperative ^125^I seed implantation and surgery alone (control group). Twenty to forty 125I seeds (0.5 mCi per seed), with a total activity in 10-30 mCi, and a matched peripheral dose (MPD) of 60-70 Gy, were implanted under direct visualization. The surgical procedure used in this study was either a radical resection, which involved an esophagectomy through a left thoracotomy with two-field lymphadenectomy, or palliative resection. The postoperative complications were observed and recorded. The location and quality assessment of J25I seeds were assessed using CT scans or X-ray imaging. The short-term efficacy was evaluated according to WHO criteria. The 1, 3, 5 and 7-year survival rates were determined on follow-up. Results: There was no displacement or loss of 125I seeds. The local recurrence rates in the intraoperative 125I seed implantation group and control group were 14.9% and 38.7%, respectively (P 〈 0.05). An objective response rate of 92% was observed in the seed implant group, which was significantly higher than 0% in the control group (P 〈 0.05). There was no significant difference between the two groups when comparing of complications (P 〉 0.05). The 1-year survival rate of the two groups were not significantly different (P 〉 0.05). However, the 3, 5 and 7-year survival rates in the united 125I group (64%, 55.3% and 8%, respectively) were statistically different from those in the control group (52%, 29.1% and 1.4%,respectively)(P 〈 0.05). Conclusion: Intraoperative 125I seed implantation is safe and effective for advanced ESCC. Seed implantation may reduce the local recurrence rate and improve survival in patients with ESCC. The MPD of 60-70 Gy, with single 125I seed activity of 0.5 mCi, is reasonable. 展开更多
关键词 esophageal squamous cell carcinoma 125i radioactive seed brachytherapy ESOPHAGECTOMY
下载PDF
Relationship between miR-7-5p expression and ^(125)I seed implantation efficacy in pancreatic cancer and functional analysis of target genes 被引量:1
8
作者 Tingting Hao Chaoqi Wang +3 位作者 Yingjie Song Wanyan Wu Xuetao Li Tao Fan 《Oncology and Translational Medicine》 CAS 2021年第4期177-182,共6页
Objective The aim of this study was to investigate the relationship between miR-7-5p expression and intertissue-^(125)I irradiation sensitivity in pancreatic cancer tissues and to analyze the function of target genes.... Objective The aim of this study was to investigate the relationship between miR-7-5p expression and intertissue-^(125)I irradiation sensitivity in pancreatic cancer tissues and to analyze the function of target genes.Methods Thirty-seven patients with unresectable pancreatic ductal adenocarcinoma(PDAC)treated with radioactive ^(125)I seed implantation were enrolled.RT-PCR was used to detect the expression level of miR-7-5p in cancer tissues and analyze the relationship between miR-7-5p expression and ^(125)I radiation sensitivity.Bioinformatic software and online tools were used to predict the miR-7-5p target genes and analyze their functional annotation and pathway enrichment.Results Radioactive ^(125)I seed implantation was followed up for 2 months.The objective response rate of the miR-7-5p high expression group was 65.0%(13/20),whereas the objective response rate of the miR-7-5p low expression group was 5.88%(1/17),and the difference between the two groups was statistically significant(χ^(2)=13.654,P<0.001).A total of 187 target genes were predicted using three databases.GO functional annotation showed that target genes were mainly involved in cellular response to insulin stimulus,regulation of gene expression by genetic imprinting,cytosol,peptidyl-serine phosphorylation,bHLH transcription factor binding,cargo loading into vesicles,cellular response to epinephrine stimulus,and nucleoplasm.KEGG pathway enrichment analysis showed that target genes were mainly involved in the ErbB signaling pathway,HIF-1 signaling pathway,axon guidance,longevity regulatory pathway,endocrine resistance,glioma,choline metabolism in cancer,and EGFR tyrosine kinase inhibitor drug resistance.Molecular complex detection analysis by Cytoscape revealed that PIGH,RAF1,EGFR,NXT2,PIK3CD,PIK3R3,ERBB4,TRMT13,and C5orf22 were the key modules of miR-7-5p target gene clustering.Conclusion The expression of miR-7-5p in pancreatic cancer tissues positively correlated with the radiosensitivity of ^(125)I seeds.Via targeted gene regulation,miR-7-5p acts on the network of multiple signaling pathways in PDAC and participates in its occurrence and development.Thus,miR-7-5p may become a predictive index of ^(125)I seed implantation therapy sensitivity in PDAC patients. 展开更多
关键词 miR-7-5p pancreatic cancer ^^(125)I radioactive seed implantation
下载PDF
The influence of interstitial brachytherapy with ~(125)I seeds on Caspase-3 and Egr-1 expressions of Lewis lung carcinoma in C57BL mice
9
作者 Xiguang Liu Tingting Song +1 位作者 Lili Du Jun Liang 《The Chinese-German Journal of Clinical Oncology》 CAS 2010年第12期688-691,共4页
Objective:The aim of our study was to explore the influence of interstitial brachytherapy with 125I seeds on Caspase-3 and Egr-1 expressions of Lewis lung carcinoma in C57BL mice.Methods:Model mice of C57BL were plant... Objective:The aim of our study was to explore the influence of interstitial brachytherapy with 125I seeds on Caspase-3 and Egr-1 expressions of Lewis lung carcinoma in C57BL mice.Methods:Model mice of C57BL were planted with Lewis lung cells (LLC) and divided into the treatment group (n=18) and the control group (n=17).In each mouse of the treatment group,two BT-125-1 Model 125I seeds with apparent activity of 9.25 MBq were implanted into the tumor;whereas in each mouse of the control group two dummy seeds were implanted.The mice survival rates of both groups were recorded after 21 days.The tumor weights and dimensions of survived mice were measured,and the tumor volume inhibition rate was calculated.T-test was performed to compare differences of tumor weights and volumes between these two groups.Routine pathological slides of tumor tissue were observed under light microscope.The expression of Caspase-3 was detected by immunohistochemical method and the expression of Egr-1 was detected by RT-PCR method.Results:The survival rates were 88.88% in the treatment group and 70.59% in the control group,the difference had no statistical significance (P > 0.05).The tumor volume inhibition rate was 71.12%.Pathological examination showed degeneration and necrosis of cancer cells at the site nearby the seed in the treated group,but the tumor cells alive were still presented nearby the seed in the control group.The expressions of Caspase-3 and Egr-1 in the treated group were higher than those in the control group (t=12.825,P < 0.01;t=7.039,P < 0.01;respectively).Conclusion:The interstitial brachytherapy with 125I seeds could significantly inhibit the growth of Lewis lung carcinoma of mice.The possible mechanism may be that 125I interstitial brachytherapy can enhance the expressions of Egr-1 and Caspase-3,which could induce tumor cellular apoptosis. 展开更多
关键词 125i seeds interstitial brachytherapy Lewis lung cell EGR-1 CASPASE-3
下载PDF
^(125)I粒子永久性植入组织间放射治疗肝癌 被引量:44
10
作者 罗开元 郑江华 +4 位作者 李波 邵庆华 杨国凯 赵泉 杨嵘 《肝胆胰外科杂志》 CAS 2004年第1期29-31,共3页
目的 :探讨12 5I组织间放射治疗肝癌的疗效。方法 :选择肝癌患者 84例 ,随机分为对照组 (A组 )与治疗组 (B组 ) ,A组 4 2例行手术治疗 (根治手术或姑息手术 )和化疗 ;B组 4 2例 ,除施行A组的治疗方案外 ,另行术中永久植入12 5I粒子。结... 目的 :探讨12 5I组织间放射治疗肝癌的疗效。方法 :选择肝癌患者 84例 ,随机分为对照组 (A组 )与治疗组 (B组 ) ,A组 4 2例行手术治疗 (根治手术或姑息手术 )和化疗 ;B组 4 2例 ,除施行A组的治疗方案外 ,另行术中永久植入12 5I粒子。结果 :术前、术后 1w及 3个月内血象虽有显著差异 ,但均在正常范围内 ,免疫指标前后变化无统计学意义。A组 :12个月、2 4个月、36个月局部复发率分别为 4 1.7%、5 0 .0 %和 5 9.5 % ;12个月、2 4个月、36个月局部生存率分别为 81.3%、6 3.4 %和 4 7.6 %。B组 :12个月、2 4个月、36个月局部复发率分别为 0、6 .7%和 11.9% ;生存率分别为 94 .7%、87.5 %和 78.4 % ,两组的局部复发率及生存率有显著性差异 (P <0 .0 5 )。结论 :12 5I组织间放射治疗肝癌方法简单、安全 ,近期疗效确切 ,是治疗癌症的理想方法之一。 展开更多
关键词 组织间放疗 ^^125 I粒子 植入 肝肿瘤
下载PDF
CT引导下放射性^(125)I粒子置入治疗脊柱转移性肿瘤的价值 被引量:26
11
作者 柳晨 王俊杰 +5 位作者 孟娜 刘晓光 姜亮 马永强 韩嵩博 袁慧书 《中国脊柱脊髓杂志》 CAS CSCD 北大核心 2011年第3期226-229,共4页
目的:探讨CT引导下放射性125I粒子置入治疗脊柱转移性肿瘤的价值。方法:14例无法手术切除或放化疗的脊柱转移性肿瘤患者,均在CT引导下行放射性125I粒子置入术。置入术前应用三维治疗计划系统制定粒子置入计划。术中根据CT影像采取不同... 目的:探讨CT引导下放射性125I粒子置入治疗脊柱转移性肿瘤的价值。方法:14例无法手术切除或放化疗的脊柱转移性肿瘤患者,均在CT引导下行放射性125I粒子置入术。置入术前应用三维治疗计划系统制定粒子置入计划。术中根据CT影像采取不同置入针排列方式种植粒子,粒子间距0.5~1.0cm。根据肿瘤大小及对放射线敏感程度置入粒子数范围26~145颗,粒子活度范围0.50~0.80mCi。术后即刻复查CT观察粒子分布情况,并再次应用三维治疗计划系统进行剂量验证。结果:14例患者均顺利完成手术。所有病例随访1~75个月,中位随访时间12.0个月。局部有效率50.0%,中位局部控制时间为26.0个月,1年、2年和3年局部控制率分别为62.5%、50.0%和37.5%。中位生存时间11.0个月,1年、2年和3年生存率分别为50.0%、41.7%和20.8%。神经功能保留率和恢复率分别为92.9%(13/14)和71.4%(10/14)。镇痛有效率和疼痛完全缓解率分别为78.6%(11/14)和64.3%(9/14)。结论:CT引导下放射性125I粒子置入治疗脊柱转移性肿瘤安全,并发症少,疗效确切,可作为不宜手术切除或放化疗患者的补充治疗方式。 展开更多
关键词 CT引导 125i粒子 脊柱肿瘤 转移 近距离治疗
下载PDF
CT引导下经皮椎体成形术联合^(125)I粒子植入治疗累及椎管的椎体转移瘤23例 被引量:15
12
作者 谢小西 吕银祥 +2 位作者 季勇 王晓伟 章国东 《介入放射学杂志》 CSCD 北大核心 2014年第3期226-230,共5页
目的探讨CT引导下经皮椎体成形术(PVP)联合125I粒子植入治疗累及椎管的椎体转移瘤的安全性和疗效。方法 23例椎体转移性肿瘤患者,累及28节椎体,每例患者受累椎体1~2节,病变涉及颈椎4节、胸椎13节,腰椎11节。均可见椎体后壁破坏,其中12... 目的探讨CT引导下经皮椎体成形术(PVP)联合125I粒子植入治疗累及椎管的椎体转移瘤的安全性和疗效。方法 23例椎体转移性肿瘤患者,累及28节椎体,每例患者受累椎体1~2节,病变涉及颈椎4节、胸椎13节,腰椎11节。均可见椎体后壁破坏,其中12例13节肿瘤侵犯到硬膜外间隙。参照术前治疗计划系统(TPS),CT引导下,颈椎采用粒子针先行125I粒子植入,改变针道后再进行PVP;胸、腰椎则采用多支粒子针单、双侧穿刺于肿瘤后部植入125I粒子,再于椎体肿瘤的前、中部注入骨水泥完成PVP治疗,随访观察相关并发症及治疗效果。结果全部病例手术成功完成,植入粒子数目为4~30颗/节,骨水泥注入量为1~6 ml/节,20例(86.9%)术后患者疼痛缓解,5处(5/28,17.8%)发生骨水泥渗漏,1例神经孔渗漏引起神经根性疼痛,经治疗后好转。全组病例未发生脊髓损伤及放射性脊髓炎等严重并发症。结论 CT引导下PVP联合125I粒子植入治疗累及椎管的椎体转移瘤,能有效缓解患者的疼痛,控制肿瘤进展,骨水泥渗漏发生率低,临床应用安全。 展开更多
关键词 椎体转移性肿瘤 经皮椎体成形术 ^^125i粒子 近距离治疗
下载PDF
^(125)I粒子植入联合动脉灌注化疗治疗不可切除性肺癌 被引量:12
13
作者 刘瑞宝 杨光 +5 位作者 崔亚利 刘岩 潘雪玲 何东风 马建群 隋林 《介入放射学杂志》 CSCD 北大核心 2009年第6期453-456,共4页
目的探讨CT引导下125I粒子植入联合动脉灌注化疗治疗不可切除肺癌的价值。方法30例不可切除性肺癌患者随机分为两组。A组14例,125I粒子植入术前或后1周内行动脉灌注化疗;B组16例,单纯125I粒子植入治疗。两组患者125I粒子植入2个月后行胸... 目的探讨CT引导下125I粒子植入联合动脉灌注化疗治疗不可切除肺癌的价值。方法30例不可切除性肺癌患者随机分为两组。A组14例,125I粒子植入术前或后1周内行动脉灌注化疗;B组16例,单纯125I粒子植入治疗。两组患者125I粒子植入2个月后行胸部CT检查,按RECIST标准判定疗效并进行生存分析。结果30例患者全部按计划完成治疗。A组植入粒子552枚,9例行了2次动脉灌注化疗;B组共植入125I粒子603枚。CT复查显示:A组完全缓解(CR)0例,部分缓解(PR)10例,稳定(SD)4例,进展(PD)0例,治疗有效率为71.4%;B组完全缓解(CR)0例,部分缓解(PR)10例,稳定(SD)5例,进展(PD)1例,治疗有效率为62.5%。两组治疗有效率差异无统计学意义(P>0.05)。1年生存率分别为78.6%和62.5%,生存期差异有统计学意义(P<0.05)。结论125I粒子植入联合动脉灌注化疗是治疗不可切除性肺癌的一种有效方法,可显著延长患者的生存期。 展开更多
关键词 肺癌 125i粒子 组织间插植 动脉灌注化疗 介入
下载PDF
^(125)I籽源与缓释化疗粒子联合植入靶向治疗进展期胰腺癌 被引量:11
14
作者 李力军 封国生 +4 位作者 刘璐 孙新臣 高宏 杨德同 张文治 《东南大学学报(医学版)》 CAS 2004年第4期246-247,261,共3页
目的 :建立放、化疗粒子联合植入法综合治疗进展期胰腺癌。方法 :2 6例进展期胰腺癌中胰头癌 19例 ,胰体癌 7例。肿瘤最大直径均大于 4cm ,大于 5cm者 5例。行内引流术 2 2例。在治疗计划指导下 ,于术中先植入 5 氟尿嘧啶 ( 5 FU)缓... 目的 :建立放、化疗粒子联合植入法综合治疗进展期胰腺癌。方法 :2 6例进展期胰腺癌中胰头癌 19例 ,胰体癌 7例。肿瘤最大直径均大于 4cm ,大于 5cm者 5例。行内引流术 2 2例。在治疗计划指导下 ,于术中先植入 5 氟尿嘧啶 ( 5 FU)缓释化疗粒子 ,再植入放射性1 2 5I粒子 ,肿瘤匹配周边剂量 (matchedperipheraldose ,MPD)为 60~ 80Gy。平均每例使用1 2 5I粒子 16粒和5 FU 10 0 0mg。结果 :全部病例经过 3~ 19个月随访观察 ,无手术并发症发生。 16例瘤体缩小超过四分之一。 2 6例患者中位生存期为 12个月 ,最长 1例随访时间为术后 19个月 ,现仍存活。结论 :放射性1 2 5I粒子和 5 展开更多
关键词 胰腺癌 ^^(125)I粒子 5-FU缓释化疗粒子 近距离治疗
下载PDF
复合^(125)I粒子植入技术联合TACE治疗肝癌合并门静脉癌栓 被引量:8
15
作者 王万胜 王晨 +7 位作者 沈健 任葆胜 印于 杨俊 唐浩桓 黄鹏 朱晓黎 倪才方 《介入放射学杂志》 CSCD 北大核心 2021年第7期680-686,共7页
目的评估复合^(125)I粒子植入技术(^(125)I粒子螺旋系统序贯肿瘤同侧分支癌栓粒子植入术)联合TACE治疗肝细胞癌(HCC)合并程氏Ⅲ型门静脉癌栓(PVTT)的安全性及有效性。方法对24例HCC合并Ⅲ型PVTT患者行门静脉主干内^(125)I粒子螺旋系统... 目的评估复合^(125)I粒子植入技术(^(125)I粒子螺旋系统序贯肿瘤同侧分支癌栓粒子植入术)联合TACE治疗肝细胞癌(HCC)合并程氏Ⅲ型门静脉癌栓(PVTT)的安全性及有效性。方法对24例HCC合并Ⅲ型PVTT患者行门静脉主干内^(125)I粒子螺旋系统植入术,随后同期行TACE治疗;7~10 d后继行肿瘤同侧分支癌栓内^(125)I粒子植入术。每6~8周行CT增强随访,并按需行再次TACE治疗。统计分析患者并发症、治疗反应率及总生存期。结果所有患者均未发生3级以上严重并发症。门静脉主干癌栓(MPVTT)的客观反应率(ORR)与疾病控制率(DCR)分别为54.2%及87.5%;肝内病变的ORR及DCR分别为29.2%及37.5%。患者中位生存期为(9.5±1.4)(95%CI,6.7~12.3)个月。结论复合^(125)I粒子植入技术联合TACE治疗HCC合并Ⅲ型PVTT是安全可行的,该模式有望进一步改善此类患者预后。 展开更多
关键词 肝细胞癌 门静脉癌栓 ^^(125)I粒子螺旋系统 ^复合^(125)I粒子植入技术 血管内近程放疗 经动脉化疗栓塞术
下载PDF
^(125)I粒子永久性植入组织间治疗胰腺癌的临床报告 被引量:28
16
作者 杨国凯 罗开元 +5 位作者 杨镛 杨嵘 王明春 毛文源 邵庆华 刘文卓 《临床外科杂志》 2003年第2期92-93,共2页
目的 探讨 12 5I永久性植入组织间治疗不能切除的胰腺癌的疗效。方法 选择晚期胰腺癌病人 12例。将12 5I粒子永久性植入癌组织区域和癌细胞转移途径的各组 (站 )淋巴结区域。术后 3~ 7d测血象及免疫指标 ,1周后摄X片观察12 5I分布状... 目的 探讨 12 5I永久性植入组织间治疗不能切除的胰腺癌的疗效。方法 选择晚期胰腺癌病人 12例。将12 5I粒子永久性植入癌组织区域和癌细胞转移途径的各组 (站 )淋巴结区域。术后 3~ 7d测血象及免疫指标 ,1周后摄X片观察12 5I分布状况 ,观察有效率。结果 有效率41.67% ,病人的平均生存时间为 9.66个月 ,其中 1例已经存活 2 5个月 ,无一例出现因植入12 5I粒子而导致的严重并发症。结论 组织间永久性植入12 5I粒子治疗恶性肿瘤方法简单、安全。 展开更多
关键词 组织间放疗 ^^125i粒子 胰腺癌
下载PDF
薄层CT对^(125)I粒子植入治疗非小细胞肺癌的质量控制和保证的意义 被引量:10
17
作者 王琳 李小东 +4 位作者 张遵城 郑广钧 郭永涛 张雪宁 戴越 《天津医药》 CAS 北大核心 2014年第4期341-344,共4页
目的探讨薄层CT扫描在125I粒子植入治疗非小细胞肺癌(NSCLC)各个环节中的临床价值。方法确诊的137例NSCLC患者,植入前CT扫描进行靶区勾画,应用治疗计划系统(TPS)制定植入方案;CT引导植入,并在植入过程中逐层扫描已植入粒子,进行实时位... 目的探讨薄层CT扫描在125I粒子植入治疗非小细胞肺癌(NSCLC)各个环节中的临床价值。方法确诊的137例NSCLC患者,植入前CT扫描进行靶区勾画,应用治疗计划系统(TPS)制定植入方案;CT引导植入,并在植入过程中逐层扫描已植入粒子,进行实时位置验证和修正;植入后CT扫描协助进行放射剂量学验证,必要时调整粒子的分布和数量,使剂量分布符合有效和微创的原则;定期随访和疗效评价也需要CT检查。结果剂量-体积直方图(DVH)均显示靶区放射剂量分布能满足处方剂量要求,周围危及器官的平均照射剂量明显低于正常组织耐受剂量;137例患者中129例(94%)植入粒子数与TPS计划的植入方案一致;植入治疗后6个月CT扫描显示局部控制总有效率为91.9%,1年和2年生存率分别为91.2%和50.4%;无治疗相关的严重并发症。结论薄层CT应用于125I粒子植入治疗NSCLC过程的各环节,尤其是在粒子植入的质量保证和质量控制方面具有重要的、不可替代的临床价值。 展开更多
关键词 非小细胞肺 碘放射性同位素 近距离放射疗法 体层摄影术 X线计算机 质量控制 125i粒子 质量保证
下载PDF
^(125)I放射粒子植入治疗前列腺癌12例临床分析 被引量:8
18
作者 朱晓应 叶林阳 +3 位作者 林茂虎 郁华亮 吴元翼 马晗 《现代泌尿外科杂志》 CAS 2009年第1期25-26,共2页
目的探讨前列腺125I放射粒子植入内放疗在前列腺癌治疗中的意义。方法依据治疗计划,在直肠B超引导下,经会阴穿刺植入前列腺125I放射粒子对12例前列腺癌行三维适形内放疗。结果全组手术顺利,平均植入125I放射粒子58粒,平均手术时间80min... 目的探讨前列腺125I放射粒子植入内放疗在前列腺癌治疗中的意义。方法依据治疗计划,在直肠B超引导下,经会阴穿刺植入前列腺125I放射粒子对12例前列腺癌行三维适形内放疗。结果全组手术顺利,平均植入125I放射粒子58粒,平均手术时间80min,术后平均住院时间7.2d。随访12例术后3个月结果:平均PSA由19.8ng/mL降至0.74ng/mL;随访6例术后6个月结果:5例PSA进一步降低,平均降至0.11ng/mL;1例升高,由0.51ng/mL升高至1.65ng/mL;无1例出现严重的并发症。结论采用永久性放射粒子植入前列腺、三维适形内放疗是一种有效、微创的治疗前列腺癌的方法。 展开更多
关键词 前列腺癌 125i放射粒子 内放疗
下载PDF
放射性^(125)Ⅰ粒子源治疗中晚期肺癌的剂量学研究和临床观察 被引量:4
19
作者 何培坤 张仲卫 +2 位作者 王桐 李林 高靖 《中国肿瘤临床》 CAS CSCD 北大核心 2007年第20期1154-1156,共3页
目的:观察放射性125Ⅰ粒子源治疗中晚期肺癌的疗效。方法:首先利用实体肿瘤等效材料,采用热释光剂量学方法,模拟实测了125I粒籽源植入瘤内后,瘤内外剂量分布,并对其剂量影响因素进行了详细研究;临床共对38例中晚期肺癌患者进行125I粒子... 目的:观察放射性125Ⅰ粒子源治疗中晚期肺癌的疗效。方法:首先利用实体肿瘤等效材料,采用热释光剂量学方法,模拟实测了125I粒籽源植入瘤内后,瘤内外剂量分布,并对其剂量影响因素进行了详细研究;临床共对38例中晚期肺癌患者进行125I粒子种植,均采用电视胸腔镜辅助小切口下实施手术,进行临床观察。结果:根据实验研究结果确定125I粒子间距为1cm时能够达到治疗量(处方剂量145Gy);本组38例患者术后恢复顺利,手术后未发生出血、气胸、肺感染、肺不张等并发症。临床观察6个月,临床分析结果显示总缓解率为63.16%,咳嗽、气短、纳差、胸疼症状明显减轻,生活质量均有不同程度的改善(P<0.05)。结论:放射性125Ⅰ粒子源对于不能手术切除的中晚期肺癌是一种安全有效的治疗方法。 展开更多
关键词 中晚期肺癌 ^^125Ⅰ粒子源 永久性组织间植入 肿瘤近距离放疗
下载PDF
关于^(125)I放射性粒子放射物理学等问题的思考 被引量:4
20
作者 张宏涛 刘士锋 +7 位作者 王从晓 陆建 赵磊 陈高 李腾 邢东明 胡效坤 滕皋军 《医学影像学杂志》 2022年第3期530-534,共5页
^(125)I放射性粒子植入属于放疗中近距离治疗范畴,分为永久性植入和暂时性植入。永久性^(125)I粒子植入因丹麦的Holm教授创建标准术式及美国的Blasko教授推广,最终以可与外放疗及手术媲美的疗效,被写入前列腺癌NCCN指南。近20年以来,在... ^(125)I放射性粒子植入属于放疗中近距离治疗范畴,分为永久性植入和暂时性植入。永久性^(125)I粒子植入因丹麦的Holm教授创建标准术式及美国的Blasko教授推广,最终以可与外放疗及手术媲美的疗效,被写入前列腺癌NCCN指南。近20年以来,在中国专家的积极研究下,应用于全身各部位实体肿瘤,取得了良好的疗效,得到国内外认可,但也观察到不同程度的并发症。纵观国内外有关^(125)I放射性粒子放射物理学的认识,一直缺乏深入研究,本文详细梳理了^(125)I粒子植入相关的物理学概念,并对几个关键问题进行解析与思考。 展开更多
关键词 ^^(125)I粒子 近距离治疗 剂量 介入性 放射学
下载PDF
上一页 1 2 6 下一页 到第
使用帮助 返回顶部